Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation
Objectives Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).Methods We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 mo...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2448024 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560791168319488 |
|---|---|
| author | Yanhua Yue Yingjie Miao Yifang Zhou Yangling Shen Luo Lu Fei Wang Yang Cao Bai He Weiying Gu |
| author_facet | Yanhua Yue Yingjie Miao Yifang Zhou Yangling Shen Luo Lu Fei Wang Yang Cao Bai He Weiying Gu |
| author_sort | Yanhua Yue |
| collection | DOAJ |
| description | Objectives Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).Methods We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 months, ≤ 12 months, ≤ 24 months, > 24 months, 6–12 months, and 12–24 months subgroups based on TTP.Results Patients in ≤ 12 months group exhibited shorter median overall survival (OS) and OS-1 compared to those in ≤ 24 months group (61.73 vs 96.10 months, P = 0.02; 54.00 vs 74.17 months, P = 0.048). ≤ 6 months group exhibited shorter median OS and OS-1 compared to 6–12 months group (33.63 vs 79.60 months, P = 0.022; 19.93 vs 65.17 months, P = 0.015). Patients in 6–12 months group had shorter median OS and OS-1 compared to those in 12–24 months group (79.60 vs 100.43 months, P < 0.001; 65.17 vs 77.17 months, P = 0.012).No significant difference in OS was observed between patients in 12–24 months and > 24 months groups. For patients who experienced progression within 12 or 24 months after remission, undergoing autologous hematopoietic stem cell transplantation (ASCT) after progression conferred a median OS and OS-2 advantage over receiving post-progression chemotherapy. Multivariable analysis confirmed that TTP was an independent predictor for OS in patients with MM.Conclusion Patients with MM who experience earlier disease progression within 12 months after remission have a worse prognosis, and post-progression ASCT can improve their survival outcomes. |
| format | Article |
| id | doaj-art-97c08d6bb7864489b19fb5c67e3f9db0 |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-97c08d6bb7864489b19fb5c67e3f9db02025-01-03T13:58:46ZengTaylor & Francis GroupHematology1607-84542025-12-0130110.1080/16078454.2024.2448024Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantationYanhua Yue0Yingjie Miao1Yifang Zhou2Yangling Shen3Luo Lu4Fei Wang5Yang Cao6Bai He7Weiying Gu8Department of Hematology, The First People’s Hospital of Changzhou, Changzhou Medical Center, Nanjing Medical University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Third Affiliated Hospital of Soochow University, Changzhou, People’s Republic of ChinaDepartment of Hematology, The First People’s Hospital of Changzhou, Changzhou Medical Center, Nanjing Medical University, Changzhou, People’s Republic of ChinaObjectives Currently, there is limited understanding regarding the prognostic significance of time to progression (TTP) after first remission in multiple myeloma (MM).Methods We conducted a retrospective analysis of clinical data from 209 patients with MM. These patients were categorized into ≤ 6 months, ≤ 12 months, ≤ 24 months, > 24 months, 6–12 months, and 12–24 months subgroups based on TTP.Results Patients in ≤ 12 months group exhibited shorter median overall survival (OS) and OS-1 compared to those in ≤ 24 months group (61.73 vs 96.10 months, P = 0.02; 54.00 vs 74.17 months, P = 0.048). ≤ 6 months group exhibited shorter median OS and OS-1 compared to 6–12 months group (33.63 vs 79.60 months, P = 0.022; 19.93 vs 65.17 months, P = 0.015). Patients in 6–12 months group had shorter median OS and OS-1 compared to those in 12–24 months group (79.60 vs 100.43 months, P < 0.001; 65.17 vs 77.17 months, P = 0.012).No significant difference in OS was observed between patients in 12–24 months and > 24 months groups. For patients who experienced progression within 12 or 24 months after remission, undergoing autologous hematopoietic stem cell transplantation (ASCT) after progression conferred a median OS and OS-2 advantage over receiving post-progression chemotherapy. Multivariable analysis confirmed that TTP was an independent predictor for OS in patients with MM.Conclusion Patients with MM who experience earlier disease progression within 12 months after remission have a worse prognosis, and post-progression ASCT can improve their survival outcomes.https://www.tandfonline.com/doi/10.1080/16078454.2024.2448024Multiple myelomafirst remissionmyeloma progressiontime to progressionpost-progression treatmentautologous hematopoietic stem cell transplantation |
| spellingShingle | Yanhua Yue Yingjie Miao Yifang Zhou Yangling Shen Luo Lu Fei Wang Yang Cao Bai He Weiying Gu Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation Hematology Multiple myeloma first remission myeloma progression time to progression post-progression treatment autologous hematopoietic stem cell transplantation |
| title | Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| title_full | Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| title_fullStr | Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| title_full_unstemmed | Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| title_short | Time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| title_sort | time to progression predicts outcome of patients with multiple myeloma that can be influenced by autologous hematopoietic stem cell transplantation |
| topic | Multiple myeloma first remission myeloma progression time to progression post-progression treatment autologous hematopoietic stem cell transplantation |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2448024 |
| work_keys_str_mv | AT yanhuayue timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT yingjiemiao timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT yifangzhou timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT yanglingshen timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT luolu timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT feiwang timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT yangcao timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT baihe timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation AT weiyinggu timetoprogressionpredictsoutcomeofpatientswithmultiplemyelomathatcanbeinfluencedbyautologoushematopoieticstemcelltransplantation |